Ramsay Generale de Sante SA (FR:GDS)
:GDS
Top Page
Ramsay Generale de Sante
(GDS)
Select Model
Select Model
Rating:60Neutral
Price Target:
€10.50
▲(12.42% Upside)
Action:ReiteratedDate:02/21/26
The score is primarily held back by weak profitability and high leverage despite stable revenue and strong cash flow trends. Technicals are supportive with the price above major moving averages and positive MACD, but valuation is pressured by losses implied by the negative P/E.
Positive Factors
Strong free cash flow growth
A 25.21% free cash flow growth rate indicates durable cash generation from operations. Persistent FCF growth provides capacity to fund maintenance capex, service debt, and invest in facility upgrades without relying solely on equity, supporting operational resilience over months.
Negative Factors
High leverage
Significant leverage increases financial risk, constraining flexibility to invest or absorb shocks. Elevated debt levels raise interest expense and refinancing needs, making the company sensitive to funding market conditions and potentially limiting strategic initiatives over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow growth
A 25.21% free cash flow growth rate indicates durable cash generation from operations. Persistent FCF growth provides capacity to fund maintenance capex, service debt, and invest in facility upgrades without relying solely on equity, supporting operational resilience over months.
Read all positive factors
Ramsay Generale de Sante (GDS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€1.13B
Dividend YieldN/A
Average Volume (3M)31.35K
Price to Earnings (P/E)―
Beta (1Y)0.19
Revenue Growth4.70%
EPS Growth-0.37%
CountryFR
Employees34,218
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.32
Shares Outstanding110,389,690
10 Day Avg. Volume445
30 Day Avg. Volume31,348
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)0.23
P/FCF Ratio2.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ramsay Generale de Sante Business Overview & Revenue Model
Company Description
Ramsay Générale de Santé SA operates hospitals in France. Its hospitals offer a range of services in the areas of anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity, ophthalmol...
How the Company Makes Money
GDS primarily generated revenue by operating private hospitals and clinics and receiving payment for patient care delivered in its facilities. Its core revenue streams typically included (1) reimbursement for inpatient and outpatient procedures an...
Ramsay Generale de Sante Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
50
Neutral
Cash Flow
65
Positive
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.32B | 5.24B | 5.01B | 4.70B | 4.30B | 4.02B |
| Gross Profit | 1.03B | 4.08B | 3.94B | 3.72B | 3.41B | 3.20B |
| EBITDA | 615.10M | 599.70M | 584.90M | 647.30M | 677.10M | 596.40M |
| Net Income | -45.90M | -54.10M | -53.90M | 49.40M | 118.40M | 65.00M |
Balance Sheet | ||||||
| Total Assets | 6.58B | 6.84B | 6.90B | 6.96B | 6.79B | 6.68B |
| Cash, Cash Equivalents and Short-Term Investments | 218.10M | 384.00M | 381.30M | 362.90M | 143.50M | 620.00M |
| Total Debt | 5.86B | 4.08B | 4.06B | 4.15B | 3.97B | 3.85B |
| Total Liabilities | 5.41B | 5.66B | 5.67B | 5.68B | 5.55B | 5.58B |
| Stockholders Equity | 1.14B | 1.15B | 1.19B | 1.25B | 1.21B | 1.07B |
Cash Flow | ||||||
| Free Cash Flow | 404.60M | 550.90M | 418.30M | 426.70M | 68.90M | 475.90M |
| Operating Cash Flow | 541.00M | 693.70M | 586.80M | 598.90M | 262.50M | 652.30M |
| Investing Cash Flow | -138.20M | -138.40M | -180.50M | -175.40M | -471.10M | -181.40M |
| Financing Cash Flow | -358.50M | -550.20M | -401.50M | -197.10M | -264.20M | -390.60M |
Ramsay Generale de Sante Technical Analysis
Positive
9.34
Price Trends
10.57
Negative
9.89
Positive
9.95
Positive
Market Momentum
-0.15
Positive
47.34
Neutral
78.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GDS, the sentiment is Positive. The current price of 9.34 is below the 20-day moving average (MA) of 10.33, below the 50-day MA of 10.57, and below the 200-day MA of 9.95, indicating a neutral trend. The MACD of -0.15 indicates Positive momentum. The RSI at 47.34 is Neutral, neither overbought nor oversold. The STOCH value of 78.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GDS.
Ramsay Generale de Sante Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €289.68M | 10.41 | 6.64% | 2.73% | 13.31% | -13.07% | |
62 Neutral | €634.83M | 3.71 | 0.12% | ― | 1.60% | ― | |
60 Neutral | €172.80M | 18.44 | -5.44% | ― | 3.79% | -797.10% | |
60 Neutral | €1.13B | -7.25 | -4.36% | ― | 4.70% | -0.37% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | €2.21B | -6.61 | -13.50% | ― | 6.30% | -100.37% | |
49 Neutral | €175.51M | 1.50 | 3.97% | ― | -7.28% | ― |
* General Sector Average
FR:GDS
Ramsay Generale de Sante
10.25
0.63
6.55%
FR:BLC
Bastide le Confort Medical
24.00
-0.30
-1.23%
FR:ALCGM
Cegedim
12.60
2.10
20.00%
FR:ELIOR
Elior Group SA
2.50
0.27
11.89%
FR:LNA
LNA Sante SA
27.80
7.03
33.85%
FR:EMEIS
Orpea SA
13.70
3.55
34.95%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.